| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | B4GALT; GALGT2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human B4GALNT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于 **B4GALNT2抗体** 的参考文献示例(注：部分文献信息为假设性概括，实际文献需通过数据库进一步验证)：
---
1. **文献名称**: *"B4GALNT2 overexpression in colorectal cancer promotes tumor progression and is associated with poor prognosis"*
**作者**: Marcisauskas, S. et al.
**摘要**: 研究利用B4GALNT2特异性抗体检测结直肠癌组织中B4GALNT2的表达，发现其表达水平与肿瘤侵袭性及患者生存率显著相关，提示其作为潜在预后标志物的价值。
2. **文献名称**: *"B4GALNT2-mediated glycosylation regulates inflammatory responses in a murine model of neurodegeneration"*
**作者**: Hanke, T. et al.
**摘要**: 通过免疫组化(使用B4GALNT2抗体)分析B4GALNT2在小鼠脑组织中的分布，发现其缺失导致神经节苷脂合成异常，加剧神经炎症反应，揭示了其在神经退行性疾病中的作用机制。
3. **文献名称**: *"Development of a monoclonal antibody against human B4GALNT2 for functional characterization in gastric cancer"*
**作者**: Zeng, Y. et al.
**摘要**: 报道了一种新型B4GALNT2单克隆抗体的开发，验证其在胃癌细胞系中的特异性，并证明B4GALNT2通过调控细胞表面糖基化修饰促进肿瘤转移。
4. **文献名称**: *"B4GALNT2 modulates integrin signaling via ganglioside biosynthesis in pancreatic cancer"*
**作者**: Lee, J. & Schnaar, R.L.
**摘要**: 研究使用B4GALNT2抗体阻断胰腺癌细胞中该酶的活性，发现其通过调节神经节苷脂代谢影响整合素信号通路，进而抑制肿瘤细胞迁移和侵袭。
---
**备注**：上述文献为示例性质，实际引用需通过PubMed、Web of Science等平台检索具体研究。建议结合关键词“B4GALNT2 antibody”“glycosylation”“cancer”等进一步筛选。
**Background of B4GALNT2 Antibody**
The B4GALNT2 (β-1.4-N-acetylgalactosaminyltransferase 2) gene encodes an enzyme involved in glycosylation, specifically catalyzing the transfer of N-acetylgalactosamine (GalNAc) to terminal galactose residues in glycoconjugates. This enzyme plays a key role in synthesizing the Sda antigen (GalNAcβ1-4[SAα2-3]Gal), a carbohydrate structure expressed on erythrocytes, intestinal tissues, and secreted glycoproteins. B4GALNT2's expression is tissue-specific, with high activity in the gastrointestinal tract, kidneys, and placenta.
Antibodies targeting B4GALNT2 are valuable tools for studying its biological roles and dysregulation in diseases. Research links B4GALNT2 to cancer, as altered expression is observed in colorectal tumors, potentially influencing cell adhesion and signaling. It also interacts with pathogens; some bacteria exploit Sda antigens for adhesion, implicating the enzyme in host-microbe interactions. Additionally, B4GALNT2 mutations are associated with rare genetic disorders, such as Tn syndrome-like phenotypes, affecting glycosylation pathways.
B4GALNT2 antibodies enable detection of protein expression via techniques like Western blotting, immunohistochemistry, and flow cytometry. They aid in exploring its regulatory mechanisms, substrate specificity, and potential as a diagnostic or therapeutic target. Recent studies also investigate its role in immune modulation, particularly in inflammatory bowel disease (IBD) and autoimmune conditions. Understanding B4GALNT2's functions through antibody-based research continues to uncover its significance in glycobiology and disease pathogenesis.
×
